EyePoint, Inc.

EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments

– Organizational focus on DURAVYUTM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 –